NAD glycohydrolases (NADases) catalyze the hydrolysis of NAD to ADP-ribose and nicotinamide. Although many members of the NADase family, including ADP-ribosyltransferases, have been cloned and characterized, the structure and function of NADases with pure hydrolytic activity remain to be elucidated. Here, we report the structural and functional characterization of a novel NADase from rabbit reticulocytes. The novel NADase is a glycosylated, glycosylphosphatidylinositol-anchored cell surface protein exclusively expressed in reticulocytes. shRNA-mediated knockdown of the NADase in bone marrow cells resulted in a reduction of erythroid colony formation and an increase in NAD level. Furthermore, treatment of bone marrow cells with NAD, nicotinamide, or nicotinamide riboside, which induce an increase in NAD content, resulted in a significant decrease in erythroid progenitors. These results indicate that the novel NADase may play a critical role in regulating erythropoiesis of hematopoietic stem cells by modulating intracellular NAD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047404 | PMC |
| http://dx.doi.org/10.1074/jbc.M114.560359 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of CD38 in mediating the effect of Bacillus on acute pancreatitis: a study of mediated Mendelian randomization.
Front Immunol
December 2024
Department of Hepatobiliary Surgery, Dongguan Kanghua Hospital, Dongguan, China.
Background: Some studies suggest a potential link between intestinal flora and acute pancreatitis (AP). However, the causal relationships between specific intestinal flora and AP, and the possible mediating role of immune cell traits, remain unclear.
Methods: A genome-wide association study (GWAS) involving 5,959 participants was conducted to identify genetic instrumental variables associated with 473 intestinal flora taxa.
Characterizing CD38 expression in terminally differentiated B cells using variable lymphocyte receptor B tetramers.
Front Immunol
November 2024
Developmental and Stem Cell Biology Program, Hospital for Sick Children, Toronto, ON, Canada.
Introduction: CD38 is an ectoenzyme receptor found on hematopoietic cells and its expression is used in the flow cytometric analysis of sub-populations of circulating B cells among peripheral blood mononuclear cells (PBMC) to aid in diagnosing patients with different antibody production defects (AbD). Monoclonal antibodies derived from the sea lamprey Variable Lymphocyte Receptor B (VLRB) are emerging as an alternative to conventional mammalian antibodies. We hypothesized that VLRB MM3 (V-CD38) which specifically recognizes CD38 in a manner correlating with its enzymatic activity could identify terminally differentiated B cells in human PBMC.
View Article and Find Full Text PDFPharmacokinetic Positron Emission Tomography Imaging of an Optimized CD38-Targeted Ga-Labeled Peptide in Multiple Myeloma: A Pilot Study.
Bioconjug Chem
December 2024
Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Multiple myeloma (MM) is an incurable disease characterized by its clinical and prognostic heterogeneity. Despite conventional chemotherapy and autologous hematopoietic stem cell transplantation, the management of relapsed and refractory MM disease poses significant challenges, both medically and socioeconomically. CD38, highly expressed on the surface of MM cells, serves as a distinct tumor biological target in MM.
View Article and Find Full Text PDFNovel Approach to Skin Anti-Aging: Boosting Pharmacological Effects of Exogenous Nicotinamide Adenine Dinucleotide (NAD) by Synergistic Inhibition of CD38 Expression.
Cells
October 2024
LG Household and Health Care R&D Center, Seoul 07795, Republic of Korea.
Nicotinamide adenine dinucleotide (NAD) is indispensable for the regulation of biological metabolism. Previous studies have revealed its role in aging and degenerative diseases, while crucially showing that supplementation with NAD or its precursors could ameliorate or reverse the progression of aging. Despite extensive evidence for the role and action of NAD in aging, its pharmacological activity on the skin, or even its mechanism, has not been elucidated.
View Article and Find Full Text PDFClinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study.
Cancer Med
October 2024
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Background: In the era of novel agents, the clinical outcomes of induction treatment and the impact of the number of high-risk cytogenetic abnormalities (HRA) in newly diagnosed multiple myeloma (NDMM) need to be explored.
Objective: Through this study, we aim to analyze the effectiveness of different induction treatments and explore the survival outcomes of patients with varying numbers of HRA.
Methods: A total of 734 patients from seven medical centers were included in our study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!